| Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease NK Majbour, NN Vaikath, KD Van Dijk, MT Ardah, S Varghese, ... Molecular neurodegeneration 11, 1-15, 2016 | 253 | 2016 |
| Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration MF Duffy, TJ Collier, JR Patterson, CJ Kemp, KC Luk, MG Tansey, ... Journal of neuroinflammation 15, 1-18, 2018 | 186 | 2018 |
| Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates ML Arotcarena, S Dovero, A Prigent, M Bourdenx, S Camus, G Porras, ... Brain 143 (5), 1462-1475, 2020 | 165 | 2020 |
| Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology NN Vaikath, NK Majbour, KE Paleologou, MT Ardah, E van Dam, ... Neurobiology of disease 79, 81-99, 2015 | 148 | 2015 |
| Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression NK Majbour, NN Vaikath, P Eusebi, D Chiasserini, M Ardah, S Varghese, ... Movement Disorders 31 (10), 1535-1542, 2016 | 115 | 2016 |
| Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial D Volc, W Poewe, A Kutzelnigg, P Lührs, C Thun-Hohenstein, ... The Lancet Neurology 19 (7), 591-600, 2020 | 108 | 2020 |
| Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration V Durante, A de Iure, V Loffredo, N Vaikath, M De Risi, S Paciotti, ... Brain 142 (5), 1365-1385, 2019 | 96 | 2019 |
| α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies I van Steenoven, NK Majbour, NN Vaikath, HW Berendse, ... Movement Disorders 33 (11), 1724-1733, 2018 | 91 | 2018 |
| Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study V Donadio, A Incensi, O El-Agnaf, G Rizzo, N Vaikath, F Del Sorbo, ... Scientific reports 8 (1), 14246, 2018 | 87 | 2018 |
| Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy O El-Agnaf, C Overk, E Rockenstein, M Mante, J Florio, A Adame, ... Neurobiology of disease 104, 85-96, 2017 | 87 | 2017 |
| Detection of oligomers and fibrils of α-synuclein by AIEgen with strong fluorescence CWT Leung, F Guo, Y Hong, E Zhao, RTK Kwok, NLC Leung, S Chen, ... Chemical communications 51 (10), 1866-1869, 2015 | 83 | 2015 |
| α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity SS Ghanem, NK Majbour, NN Vaikath, MT Ardah, D Erskine, NM Jensen, ... Proceedings of the National Academy of Sciences 119 (15), e2109617119, 2022 | 78 | 2022 |
| Antibodies against alpha‐synuclein: tools and therapies NN Vaikath, I Hmila, V Gupta, D Erskine, M Ingelsson, OMA El‐Agnaf Journal of Neurochemistry 150 (5), 612-625, 2019 | 65 | 2019 |
| Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. K Dong-Kyu, L Hee-Sun, K Ichiro, NV Yhong-Hee, Shim Nishant, ... Autophagy, 2016 | 61 | 2016 |
| Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy JZ Wu, M Ardah, C Haikal, A Svanbergsson, M Diepenbroek, NN Vaikath, ... Translational neurodegeneration 8, 1-15, 2019 | 54 | 2019 |
| Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease NK Majbour, D Chiasserini, NN Vaikath, P Eusebi, T Tokuda, ... Scientific reports 7 (1), 40263, 2017 | 53 | 2017 |
| Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders H Javed, SA Menon, KM Al-Mansoori, A Al-Wandi, NK Majbour, MT Ardah, ... Molecular Therapy 24 (4), 746-758, 2016 | 49 | 2016 |
| CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers NK Majbour, JO Aasly, E Hustad, MA Thomas, NN Vaikath, N Elkum, ... Translational neurodegeneration 9, 1-10, 2020 | 40 | 2020 |
| Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates M Bourdenx, A Nioche, S Dovero, ML Arotcarena, S Camus, G Porras, ... Science advances 6 (20), eaaz9165, 2020 | 38 | 2020 |
| Heterogeneity in α‐synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease NN Vaikath, D Erskine, CM Morris, NK Majbour, K Vekrellis, JY Li, ... Neuropathology and applied neurobiology 45 (6), 597-608, 2019 | 31 | 2019 |
